JANX Price Prediction Next Week
Analysis and Insights
News and Sentiment Analysis:
- Scotiabank has lowered its price target for Janux Therapeutics (JANX) from $62 to $41, maintaining a Sector Perform rating, citing unmet benchmarks in the Phase 1 trial of JANX007.
- Despite this, other analysts have issued strong buy ratings, highlighting the promising potential of JANX's lead asset and strategic plans.
- Insider trading activity shows the Chief Business Officer sold 901 shares, while institutional investors have increased their positions in JANX.
Technical Indicators:
- RSI (14): 35.60 (Oversold range, indicating potential rebound).
- MACD: -2.11 (Bearish signal line crossover).
- Stochastic Oscillator: 35.36 (Above 20, indicating bullish divergence).
- Fibonacci Levels: Resistance at $32.81, Support at $28.53.
Price Action:
- Current Price: $31.74 (as of 2025-03-24).
- Volume: 709,118 (above average, indicating interest).
- SMA: Trading near 20-day SMA ($31.28), below 50 and 200-day SMAs.
Prediction and Recommendation:
Based on the oversold RSI and potential bullish divergence in the Stochastic Oscillator, JANX may experience a short-term rebound. However, the overall bearish trend and Scotiabank's price target reduction suggest caution.
Predicted Price Range: $31.74 to $32.81.
Recommendation: Buy on dips near $31.74, targeting resistance at $32.81, with a stop-loss at $30.67.
JANX Similar Chart Price Prediction
The price of JANX is predicted to go up 6.22%, based on the high correlation periods with PRAA. The similarity of these two price pattern on the periods is 97.31%.
JANX
PRAA
Up: 6.22%Similarity: 97.31%
JANX Revenue Forecast
JANX EPS Forecast
JANX FAQs
What is JANX revenue forecast for next quarter？
JANX Analyst's Forecast
Josh Schimmer
Cantor Fitzgerald
Buy
2024-12-11
Price Target
$200
Upside
+224.89%
Cantor Fitzgerald raised the firm's price target on Janux Therapeutics to $200 from $100 and keeps an Overweight rating on the shares. Janux Therapeutics reported data for JANX007 for metastatic castration-resistant prostate cancer patients that far exceeded the expectations the firm had captured in a survey a few week ago, and the data may continue to get better as the higher dose cohorts mature, the analyst tells investors in a research note. The firm says there were only minor things to nit-pick and that '007 demonstrated "unprecedented" rates of PSA50, PSA90, overall response rate, and a very well tolerated profile.
Bradley Canino
Stifel
Strong Buy
2024-12-03
Price Target
$70 → $115
Upside
+76.95%
Jeffrey La Rosa
Leerink Partners
Buy
2024-12-03
Price Target
$79 → $91
Upside
+40.02%
